Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 10.1%

Inhibikase Therapeutics, Inc. (NYSE:IKT – Get Rating) shares shot up 10.1% during mid-day trading on Monday . The company traded as high as $0.87 and last traded at $0.87. 416 shares were traded during mid-day trading, a decline of 100% from the average session volume of 128,280 shares. The stock had previously closed at $0.79.

The company’s fifty day moving average is $0.96 and its 200-day moving average is $1.24. The company has a market capitalization of $21.95 million, a PE ratio of -1.12 and a beta of 1.25.

Inhibikase Therapeutics (NYSE:IKT – Get Rating) last issued its quarterly earnings results on Monday, May 16th. The company reported ($0.18) earnings per share (EPS) for the quarter. Inhibikase Therapeutics had a negative return on equity of 41.29% and a negative net margin of 964.94%. The company had revenue of $0.05 million during the quarter.

A number of institutional investors and hedge funds have recently bought and sold shares of IKT. Renaissance Technologies LLC acquired a new stake in shares of Inhibikase Therapeutics during the fourth quarter worth about $296,000. Hamilton Lane Advisors LLC purchased a new stake in shares of Inhibikase Therapeutics during the first quarter worth approximately $245,000. Retirement Planning Co of New England Inc. purchased a new stake in Inhibikase Therapeutics in the 4th quarter valued at $216,000. Redmond Asset Management LLC purchased a new stake in Inhibikase Therapeutics in the 1st quarter valued at $182,000. Finally, Millennium Management LLC purchased a new stake in Inhibikase Therapeutics in the 3rd quarter valued at $192,000. Institutional investors own 24.49% of the company’s stock.

Inhibikase Therapeutics Company Profile (NYSE:IKT)

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.

Further Reading